All News

Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.

Dr. Elena Christofides on why patients who don't respond to diabetes medications deserve a diagnostic workup — not a non-adherence label.

A new benchmarking survey of 33 biotech and medtech leaders reveals a leadership community operating in crisis mode — and what that means for how the industry needs to rethink peer support, advisory and the isolation built intothe CEO role itself.

Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan argues health care needs an orchestration layer rather than more point solutions, and Nacho Quinones and Aisling O'Loughlin make the case for synthetic advisory boards in biopharma decision-making.

The advantages of synthetic advisory boards in stress-testing hypotheses and iterating across a greater scope of scenarios than live boards allow.

Novartis shareholders share deepened trust issues around the company's dealmaking strategy.

As leaders, we must evaluate solutions to fragmentation by asking the right questions.

Ten life sciences board directors on AI's three hardest questions: developing the next generation of talent, accountability for speed, and board fluency.

Dr. Elena Christofides on why treatment failure in diabetes should trigger a cortisol screen — not an assumption of non-adherence.

Why clinical out-of-home marketing has finally become responsive after decades of running static, scheduled messages.

A “maturity curve” can help organizations move engagement beyond performative gestures to a strategic asset.

How agentic artificial intelligence is transforming the value chain from discovery to commercialization.

Unmet need is likely a new battlefield impacting prior authorization.

Artisan Partners' David Samra is publicly calling for Novartis to overhaul its board and compensation structure following back-to-back trial failures.

Dr. Elena Christofides on why the overnight dexamethasone suppression test is the only cortisol screen that actually identifies HPA dysfunction.

Kura Oncology spins out Caspian Therapeutics to apply its menin inhibitor expertise to diabetes — with Eli Lilly validating the science.

Model N's Jesse Mendelsohn examines the growing stakes surrounding the 340B Drug Pricing Program — and how claims data, rebate models and simmering legal challenges are influencing manufacturer response and strategy today.

HHS confirms permanent directors for CDER and CBER and creates FDA's first-ever Deputy Commissioner for Technology and AI.

Dr. Elena Christofides on why cortisol dysregulation may explain why so many patients fail to respond to GLP-1 and incretin therapies.

Back Bay’s director discusses why IBD remains underserved — JAK inhibitor constraints, emerging oral mechanisms, and the durability gap.

Aptar Pharma and Aceso Therapeutics team up to advance an inhaled cystic fibrosis therapy, Moonwalk Biosciences raises a $70 million Series B for its fat-targeted obesity platform, and Sebastian Arana of MilliporeSigma talks through the real cost of manufacturing flexibility.

Aptar Pharma and Aceso Therapeutics have partnered to advance ACT-101, an antisense oligonucleotide targeting the underlying mechanisms of cystic fibrosis.

Moonwalk Biosciences has closed a $70 million Series B to advance its adipose-targeted RNAi platform toward first-in-human studies.

Sebastian Arana, head of process solutions at MilliporeSigma, discusses the operational tradeoffs facilities face as they move toward multi-modality production and the persistent cost and scale-up challenges shaping cell and gene therapy, mRNA, and ADC manufacturing.

Back Bay’s director discusses why IBD remains underserved — JAK inhibitor constraints, emerging oral mechanisms, and the durability gap.

Christian Thienel on the oral IBD mechanisms generating the most excitement — SIK2, oral IL-23, TYK2 — and why multiple could succeed.

Carelon Research's Mark Cziraky on why analyzing RWD in place — rather than licensing it out — is reshaping how evidence gets generated.

Ionis wins FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, Pharmaceutical Executive’s weekly biotech roundup gathers analyst reaction to the week's biggest stories, and Nate Hill of Strive Pharmacy talks through the regulatory uncertainty around compounded peptides.